GROUP DETAILS

Name ID Roll

MD. Abu Bakr Siddique 1310758030 13

Akib Ahmed 1220360630 04

SK. Shamsad Hossain 1320292030 20

Akash Alam 1320291630 19

Iftekharul Alam 1410410630 36

Mahtab Hossain Khan 1321135630 24

Ridwan Abir 1321136630 25

Md. Adeel Anjum 1321311630 27

COMPANY BACKGROUND
 HISTORY

INCEPTA PHARMACEUTICALS LTD. IS A LEADING PHARMACEUTICAL COMPANY IN BANGLADESH

ESTABLISHED IN THE YEAR 1999
BIG MANUFACTURING FACILITY LOCATED AT SAVAR
THE COMPANY SPECIALIZES IN VALUE ADDED HIGH TECHNOLOGY DOSAGE
AFTER BEING SUCCESSFUL LOCALLY THEY ARE OPERATION GLOBALLY
ACCREDITED WITH THE UK MHRA GMP CERTIFICATE
SINCE JULY 2011 THEY ARE MARKETING PRODUCTS IN UK
 MISSION & VISION

MISSION- PROVIDE QUALITY HEALTHCARE PRODUCTS AND SERVICES FOR THE BENEFIT OF
HUMANITY IN THE BEST POSSIBLE WAY THROUGH INNOVATION AND DIVERSIFICATION.
VISION- OUR VISION IS TO BECOME A TRUSTED HEALTHCARE COMPANY TO ENSURE BETTER
HEALTH FOR EVERYONE, EVERYWHERE
 VALUE CHAIN ANALYSIS

INCEPTA HAS A LARGE DISTRIBUTION NETWORK.

PRODUCTS AVAILABLE IN EVERY SINGLE DRUG STORE.
PRODUCTS ALSO SUPPLIED TO REMOTE AREAS.
THERE IS A LARGE FLEET OF TRANSPORT INCLUDING REFRIGERATOR TRUCKS FOR SUPPLYING
TEMPERATURE SENSITIVE PRODUCTS.
LOWER PRICE COMPARED TO COMPETITORS BOTH LOCALLY AND INTERNATIONALLY.
WHY THEY INVESTED IN THE FOREIGN
MARKET?
 SWOT ANALYSIS
STRENGTHS:
STRONG BRAND IMAGE- IMPROVED BRAND IMAGE DUE TO EXPORTS IN 40 COUNTRIES.
WIDE RANGE OF PRODUCTS- GENERIC MEDICINES AS WELL AS SPECIALIZED MEDICINES.
COMPETITIVE PRICE IN BOTH DOMESTIC AND INTERNATIONAL MARKETS.
LARGE DOMESTIC MARKET WITH REASONABLE GROWTH RATE: CONSUMER SPENDING IS INCREASING IN HEALTH CARE
PARALLEL TO POPULATION INCREASE.

WEAKNESSES:
ABSENCE OF INTERNATIONAL STANDARD QUALITY CONTROL AND TESTING LABORATORY
LITTLE RESEARCH AND DEVELOPMENT ON NEW MOLECULE DEVELOPMENT ETC.
 SWOT ANALYSIS (CONTINUED)

OPPORTUNITIES:
LARGE POTENTIAL FOR EXPORT MARKET EXPANSION
SCOPE FOR PRODUCT DIVERSIFICATION
SCOPE TO TAKE ADVANTAGE OF PARALLEL IMPORTS.
RESEARCH AND DEVELOPMENT ACTIVITIES MAY BE INITIATED WITH EXTERNAL SUPPORT.

THREATS:
CHEAPER MEDICINE FROM CHINA AND INDIA.
COUNTRIES SUPPLYING PRODUCTS THROUGH UNAUTHORIZED CHANNELS.
INCREASE OF PRICE OF RAW MATERIALS.
 SUMMARIZING THE SWOT
AVAILING OPPORTUNITIES USING STRENGTH:
USING PARALLEL IMPORTS TO AVAIL THE ADVANTAGE OF LARGE DOMESTIC MARKET.
ENTER NEW MARKETS TO AVAIL THE ADVANTAGE OF BEING VIEWED AS A CHEAP BUT QUALITY MEDICINE
PROVIDER.
DIVERSIFY TO HERBAL MEDICINES AND MEDICINES FOR ANIMALS TO USE THE EXISTING RESOURCES MORE
EFFICIENTLY.

WHY EXPORTING?
MARKET SEEKING PURPOSE- A BIGGER MARKET WILL ALLOW THE COMPANY TO PRODUCE MORE PRODUCTS, THUS
IT WILL LET THE COMPANY TO AVAIL THE ADVANTAGES OF ECONOMIES OF SCALE, THUS COMPETING BETTER WITH
CHINA AND INDIA.
WHAT FACTORS DID THEY CONSIDER WHILE
INVESTING IN THE FOREIGN MARKET?
 EXTERNAL FACTORS

PARTNERSHIPS AND TECHNOLOGY TRANSFER IN EXPORT OPERATION.

CURRENTLY THE COMPANY IS EXPLORING DISTRIBUTORSHIP, CONTRACT MANUFACTURING, IN
LICENSING, TECHNOLOGY PARTNERSHIP AND MANY OTHER FORMS OF COOPERATION IN
VARIOUS COUNTRIES AROUND THE WORLD.
 INDUSTRIAL FACTORS

INCEPTAS EXPORT TO THE WORLD.

INCEPTA CURRENTLY SELLS ITS PRODUCT IN MANY COUNTRIES OF ASIA, AFRICA, CENTRAL AND
LATIN AMERICA AND HAS STARTED TO SELL IN EUROPE.
WHAT PROCESS DID THEY FOLLOW?
 WHAT WAS THE SELECTION PRICESS TO GOT TO
OTHER MARKETS?
IT ONLY TAKES THIRTEEN DAYS TO SET UP A COMPANY IN THE UNITED KINGDOM
THE FOREIGN COMPANIES ARE ALSO TREATED AS A LOCAL COMPANY ONCE IT HAS BEEN
REGISTERED
LOW TAXATION MAKES THE ENVIRONMENT INVESTOR-FRIENDLY AND LONDON IS ONE OF THE
WORLD'S LEADING FINANCE CAPITALS
CURRENTLY INCEPTA EXPORTS TO 60 DIFFERENT COUNTRIES AROUND THE WORLD
 THE STAGES OF SELECTION

SUBSTITUTE PRODUCTS AND ACCESS TO ALL THE RAW MATERIALS.

COUNTRYS GOVERNMENT REGULATIONS AND POLICIES ON INVESTMENT.
AVAILABILITY OF APPROPRIATE AND SKILLED HUMAN RESOURCE.
ECONOMIC GROWTH OF THE COUNTRY.
POLITICAL STABILITY.
COST AND EASE OF DOING BUSINESS.
 HOW WAS IT POSSIBLE?
WAS THERE ANY PROBLEM?

ACQUISITION
THIS FIRM ACQUIRE, THE FINANCIAL PUBLIC RELATIONS AND MARKETING GROUP, IS IN TALKS
OVER AN ALL-SHARE MERGER WITH RIVAL HUNTSWORTH.

PROBLEM
INTEGRATING FOREIGN SUBSIDIARIES INTO THE PARENTS SYSTEM.
STRATEGY OF THE FIRM
 WHAT HAD BEEN THE MAJOR AND OTHER IMPORTANT ISSUES THEY
FACED DURING THE INTERNATIONALIZATION PROCESS?

KEY MANAGERIAL POSITIONS

CULTURAL BARRIERS
TAX SYSTEMS
 FUTURE PLANS

INCEPTA PHARMACEUTICALS LIMITED, SWISS BIOTECH EQUIPMENT MANUFACTURER

BIOENGINEERING AND GERMAN AMS TECHNOLOGY HAVE JOINTLY LAUNCHED A COMPANY
CALLED SWISS BIOHYGIENIC EQUIPMENTAT RADISSON BLU ON 28TH SEPTEMBER, 2016.

FROM THE VERY BEGINNING, INCEPTA HAS FOCUSED ON LAUNCHING NEWER AND
INNOVATIVE PRODUCTS. HIGH INVESTMENT IN R&D AND ADVANCED TECHNOLOGY HAS
ALLOWED THE COMPANY TO LAUNCH 429 GENERICS WITH 783 PRESENTATIONS, 158 OF
WHICH WERE INTRODUCED FIRST TIME IN BANGLADESH.
ENDING REMARKS FROM OUR
PRESENTATION
 CONCLUSION

INCEPTA STRONGLY BELIEVES THAT COMMITMENT TOWARDS PEOPLE AND THE SOCIETY AS A
WHOLE POSITIVELY CONTRIBUTES TOWARDS ITS BUSINESS OBJECTIVE.
INCEPTA ADOPTS DIFFERENT STRATEGIES, WHICH CREATE A SUSTAINABLE ADVANTAGE FOR THE
COMPANY.
IT IS THE FIRST BANGLADESHI PHARMACEUTICAL COMPANY TO IMPLEMENT SAP TO MANAGE
RESOURCES THROUGHOUT THE COMPANY OPERATION.
THIS WORLD CLASS RESOURCE MANAGEMENT SYSTEM ALLOWS THE COMPANY TO BECOME MORE
EFFICIENT AND EFFECTIVE IN ITS DAY TO DAY OPERATION.
INCEPTA IS TAKING SPECIAL EFFORTS TO ENSURE PRESENCE IN THE REST OF THE GLOBE.